<DOC>
	<DOCNO>NCT01155284</DOCNO>
	<brief_summary>Sanford Research/USD propose study combination therapy oral administration sitagliptin lansoprazole versus placebo preservation pancreatic beta cell still present patient recent-onset diabetes possibly regenerate beta cell , safely down-regulating autoimmune response direct beta cell .</brief_summary>
	<brief_title>Combination Therapy With Sitagliptin Lansoprazole Restore Pancreatic Beta Cell Function Recent-Onset Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diagnosis type 1 diabetes , base American Diabetes Association criterion , recently diagnose ( within 6 month Screening ) confirm presence least 1 diabetes relate autoantibody ( either glutamic acid decarboxylase [ GAD ] , insulinomaassociated protein [ IA 2 ] , insulin , latter measure within 10 day start insulin therapy ) . Male female age 11 45 year , inclusive . Able swallow study capsule . Willing comply `` intensive diabetes management '' direct investigator , goal maintain blood glucose close American Diabetes Association recommendation possible . Willing comply schedule study visit protocol requirement . Use GLP 1R agonist DPP 4 inhibitor within 1 month enrollment . Use PPI within 1 month enrollment . Use oral hypoglycemic agent within 1 month enrollment use thiazolidinediones within 3 month enrollment ( although thiazolidinediones may use &lt; 7days enrollment ) . Females childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period . Females pregnant breastfeeding time enrollment . Subjects follow condition : Renal insufficiency , define estimate glomerular filtration rate ( GFR ) less 50 mL/min Screening , calculate use Modification Diet Renal Disease ( MDRD ) equation . History serious hypersensitivity reaction sitagliptin lansoprazole , anaphylaxis angioedema . Severe hepatic insufficiency . History pancreatitis gallbladder disease Any significant medical condition , opinion investigator medical monitor would interfere study participation .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>HGB A1C</keyword>
	<keyword>Beta Cell Regeneration</keyword>
</DOC>